102 related articles for article (PubMed ID: 17926197)
1. Serum antibodies against prostasomal clusterin in prostate cancer patients.
Ronquist KG; Carlsson L; Ronquist G; Semjonow A; Wülfing C; Larsson A
Scand J Clin Lab Invest; 2008; 68(3):219-27. PubMed ID: 17926197
[TBL] [Abstract][Full Text] [Related]
2. The antibody response to Propionibacterium acnes is an independent predictor of serum prostate-specific antigen levels in biopsy-negative men.
Shannon BA; Cohen RJ; Garrett KL
BJU Int; 2008 Feb; 101(4):429-35. PubMed ID: 17850358
[TBL] [Abstract][Full Text] [Related]
3. Antiprostasome antibody titres in benign and malignant prostate disease.
Minelli A; Ronquist G; Carlsson L; Mearini E; Nilsson O; Larsson A
Anticancer Res; 2005; 25(6C):4399-402. PubMed ID: 16334115
[TBL] [Abstract][Full Text] [Related]
4. Serum level of clusterin and its density in men with prostate cancer as novel biomarkers reflecting disease extension.
Miyake H; Muramaki M; Furukawa J; Kurahashi T; Fujisawa M
Urology; 2010 Feb; 75(2):454-9. PubMed ID: 19854485
[TBL] [Abstract][Full Text] [Related]
5. Antiprostasome antibodies: possible serum markers for prostate cancer metastasizing liability.
Larsson A; Ronquist G; Wülfing C; Eltze E; Bettendorf O; Carlsson L; Nilsson BO; Semjonow A
Urol Oncol; 2006; 24(3):195-200. PubMed ID: 16678048
[TBL] [Abstract][Full Text] [Related]
6. Antiprostasome antibodies are not an appropriate prognostic marker for prostate cancer.
Stewart AB; Delves GH; Birch BR; Cooper AJ; Lwaleed BA
Scand J Urol Nephrol; 2009; 43(2):104-8. PubMed ID: 18979375
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of serum and urine clusterin as a potential tumor marker for urinary bladder cancer.
Stejskal D; Fiala RR
Neoplasma; 2006; 53(4):343-6. PubMed ID: 16830064
[TBL] [Abstract][Full Text] [Related]
8. Prostasome-derived proteins capable of eliciting an immune response in prostate cancer patients.
Ronquist KG; Carlsson L; Ronquist G; Nilsson S; Larsson A
Int J Cancer; 2006 Aug; 119(4):847-53. PubMed ID: 16557587
[TBL] [Abstract][Full Text] [Related]
9. Increased urokinase-type plasminogen activator receptor and epidermal growth factor receptor in serum of patients with prostate cancer.
Milanese G; Dellabella M; Fazioli F; Pierpaoli E; Polito M; Siednius N; Montironi R; Blasi F; Muzzonigro G
J Urol; 2009 Mar; 181(3):1393-400. PubMed ID: 19157433
[TBL] [Abstract][Full Text] [Related]
10. Rapid and simple detection of a mycobacterium circulating antigen in serum of pulmonary tuberculosis patients by using a monoclonal antibody and Fast-Dot-ELISA.
El-Masry S; El-Kady I; Zaghloul MH; Al-Badrawey MK
Clin Biochem; 2008 Feb; 41(3):145-51. PubMed ID: 18082139
[TBL] [Abstract][Full Text] [Related]
11. Mitochondrial DNA in serum of patients with prostate cancer: a predictor of biochemical recurrence after prostatectomy.
Ellinger J; Müller SC; Wernert N; von Ruecker A; Bastian PJ
BJU Int; 2008 Aug; 102(5):628-32. PubMed ID: 18410441
[TBL] [Abstract][Full Text] [Related]
12. Lysosomal and prostasomal hydrolytic enzymes and redox processes and initiation of prostate cancer.
Tappel A
Med Hypotheses; 2005; 64(6):1170-2. PubMed ID: 15823710
[TBL] [Abstract][Full Text] [Related]
13. Serum active hepatocyte growth factor (AHGF) in benign prostatic disease and prostate cancer.
Yasuda K; Nagakawa O; Akashi T; Fujiuchi Y; Koizumi K; Komiya A; Saiki I; Fuse H
Prostate; 2009 Mar; 69(4):346-51. PubMed ID: 19021204
[TBL] [Abstract][Full Text] [Related]
14. Evaluating efficacy of plasmapheresis for patients with pemphigus using desmoglein enzyme-linked immunosorbent assay.
Nagasaka T; Fujii Y; Ishida A; Handa M; Tanikawa A; Amagai M; Nishikawa T
Br J Dermatol; 2008 Apr; 158(4):685-90. PubMed ID: 18241273
[TBL] [Abstract][Full Text] [Related]
15. [Serum anti-p53 antibodies in gastric cancer patients].
Lawniczak M; Bielicki D; Sulzyc-Bielicka V; Marlicz K; Starzyńska T
Pol Merkur Lekarski; 2007 Sep; 23(135):192-5. PubMed ID: 18080693
[TBL] [Abstract][Full Text] [Related]
16. Neuroendocrine differentiation in stage D2 prostate cancers.
Kamiya N; Suzuki H; Kawamura K; Imamoto T; Naya Y; Tochigi N; Kakuta Y; Yamaguchi K; Ishikura H; Ichikawa T
Int J Urol; 2008 May; 15(5):423-8. PubMed ID: 18452460
[TBL] [Abstract][Full Text] [Related]
17. Detection of S100 protein from prostatic cancer patients using anti-S100 protein antibody immobilized on POS-PVA discs.
Melo-Júnior MR; Filho JL; Cavalcanti CL; Patu VJ; Beltrão EI; Carvalho LB
Biotechnol Bioeng; 2007 May; 97(1):182-7. PubMed ID: 17013937
[TBL] [Abstract][Full Text] [Related]
18. Serum resistin levels in benign prostate hyperplasia and non-metastatic prostate cancer: possible role in cancer progression.
Housa D; Vernerova Z; Heracek J; Cechak P; Rosova B; Kuncova J; Haluzik M
Neoplasma; 2008; 55(5):442-6. PubMed ID: 18665756
[TBL] [Abstract][Full Text] [Related]
19. Prostasome antigens as targets for sperm agglutinating antibodies demonstrated by 1-D gel electrophoresis and immunoblottings.
Carlsson L; Larsson A; Ronquist G; Nilsson BO
Int J Androl; 2004 Dec; 27(6):360-7. PubMed ID: 15595955
[TBL] [Abstract][Full Text] [Related]
20. Prothrombotic effect of prostasomes of metastatic cell and seminal origin.
Babiker AA; Hamad OA; Sanchez J; Ronquist G; Nilsson B; Ekdahl KN
Prostate; 2007 Mar; 67(4):378-88. PubMed ID: 17219380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
